Sign in

CIK 0001783328

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

TScan Therapeutics, Inc.

Sign in to watch
Ticker
TCRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
825282075
Phone
+1 857-399-9500
Business address
830 WINTER STREET, WALTHAM, MA, 02451
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-10-01 MacBeath Gavin Chief Executive Officer Grant or award +1,000,000 1,049,767
2026-10-01 ZDRAVESKI ZORAN See Remarks Grant or award +300,000 304,716
2026-05-20 BAKER BROS. ADVISORS LP Director Grant or award · Non- Qualified Stock Option (right to buy) +67,000 67,000
2026-05-20 BAKER BROS. ADVISORS LP Director Grant or award · Non- Qualified Stock Option (right to buy) +67,000 67,000
2026-05-20 Woods Keith Director Grant or award · Stock Option (Right to Buy) +67,000 67,000
2026-05-20 Nicholson Garry A Director Grant or award · Stock Option (Right to Buy) +67,000 67,000
2026-05-20 Gruia Gabriela Director Grant or award · Stock Option (Right to Buy) +67,000 67,000
2026-05-20 Dorton Katina Director Grant or award · Stock Option (Right to Buy) +67,000 67,000
2026-05-20 Klencke Barbara Director Grant or award · Stock Option (Right to Buy) +67,000 67,000
2026-01-20 Amello Jason Chief Financial Officer Grant or award · Stock Option (Right to Buy) +350,000 350,000
2026-01-20 MacBeath Gavin Chief Executive Officer Grant or award · Stock Option (Right to Buy) +1,165,000 1,165,000
2026-01-20 Dworak Leiden See Remarks Grant or award · Stock Option (Right to Buy) +100,000 100,000
2026-01-20 Louis Chrystal Chief Medical Officer Grant or award · Stock Option (Right to Buy) +420,000 420,000
2026-01-20 ZDRAVESKI ZORAN See Remarks Grant or award · Stock Option (Right to Buy) +350,000 350,000
2025-12-23 Lynx1 Capital Management LP 10% owner Purchase +6,232 $0.90 $6K 8,019,148
2025-12-22 Lynx1 Capital Management LP 10% owner Purchase +75,500 $0.90 $68K 8,012,916
2025-12-19 Lynx1 Capital Management LP 10% owner Purchase +80,069 $0.90 $72K 7,937,416
2025-06-30 BAKER BROS. ADVISORS LP Director Grant or award · Non- Qualified Stock Option (right to buy) +67,000 67,000
2025-06-30 BAKER BROS. ADVISORS LP Director Grant or award · Non- Qualified Stock Option (right to buy) +67,000 67,000
2025-06-30 Klencke Barbara Director Grant or award · Stock Option (Right to Buy) +67,000 67,000

Page 1 of 8 · 144 trades